Compare Merck & Co., Inc. (MRK) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Suncor Energy Inc. — how do they compare? Merck & Co., Inc. trades at $148.23 (market cap $366.28B), while Suncor Energy Inc. trades at $69.3 (market cap $79.39B). The key difference: Merck & Co., Inc. is far larger — about 4.6× Suncor Energy Inc.'s market cap, and Suncor Energy Inc. pays the higher dividend (2.55%). Which is the better fit depends on your goals.
| MRK | SU | |
|---|---|---|
Market Cap | $366.28B | $79.39B |
Sector | Health | Energy |
52-Week High | $156.43 | $69.73 |
52-Week Low | $77.60 | $38.17 |
Enterprise Value | $413.04B | $86.13B |
Dividend Yield | 2.29% | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Suncor Energy (SU) trades at $67.89, up 0.83% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 12.54, net margin of 14.7%, and robust cash flow generation. Recent Q2 2026 earnings beat expectations at $2.27 EPS versus $2.14 expected. Analyst consensus is overwhelmingly positive with 74% buy ratings. The company maintains solid balance sheet metrics with debt-to-asset ratio improving to 11.1% in 2025.
SU presents a compelling value opportunity with attractive valuation multiples and strong profitability. Near-term catalysts include leadership transition with Peter Zebedee becoming CEO in 2027 and continued shareholder returns via dividends and buybacks. Key risks include commodity price volatility and operational challenges from weather disruptions. The stock's current technical setup supports further upside potential toward resistance at $69-71.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
